Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
eTheRNA immunotherapies NV
eTheRNA immunotherapies NV
Activities:
Pharmaceutical
X
LinkedIn
Trending Articles
Innovation in generics: increased efficiency through peptide API synthesis expertise
Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues
COVID-19 still a significant risk for the immunocompromised, study finds
AstraZeneca's INFORM study highlights the persistent danger of COVID-19 for the immunocompromised despite the vaccination scheme
US court lifts modified consent decree on Xellia’s Cleveland facility
The Modified Consent Decree imposed on Xellia's Cleveland facility in 2016 has been vacated, receiving a VAI
Lonza's AI-enabled small molecule development tool launches
The company's AI-enabled Route Scouting Service will optimise synthetic route identification when identifying novel APIs
Autoscribe Informatics’ new Australia office supports business growth
The company's move to West Lakes Adelaide expands its ability to service the Asia Pacific region in digitalising laboratory information
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Manufacturing
etherna appoints Shelly West as Business Development Director, US
Shelly arrives from Cellpoint Biosciences and will be in charge of expanding etherna's US customer base
Ingredients
LNP formulation improves mRNA vaccine efficacy and tolerability
S-Ac7-DOG encapsulated mRNA demonstrated markedly higher transfection, lower reactogenicity, and higher accumulation in the vaccine draining lymph nodes
Research & Development
Almirall and etherna to develop mRNA-based therapies in medical dermatology
The collaboration leverages etherna’s proprietary mRNA and lipid nanoparticle (LNP) technology with Almirall’s expertise in the dermatology space
Manufacturing
eTheRNA Manufacturing announces LNP development service
The service uses the company’s proprietary lipid libraries and proprietary formulations to facilitate targeted delivery and tailored biodistribution solutions
Research & Development
eTheRNA announces mRNA research agreement with Merck
The ongoing pandemic has underlined the capability for mRNA vaccines as a therapeutic modality
Finance
eTheRNA immunotherapies opens Hong Kong office
The subsidiary will support and build on the company’s growing activities in China and broader Asia-Pacific
Research & Development
New eTheRNA led international consortium to develop COV-2 mRNA vaccineCV-19
eTheRNA launches an international consortium and starts development of cross-strain protective CoV-2 mRNA vaccine for high risk populations
Subscribe now